Treatment of post-kala-azar dermal leishmaniasis with sodium stibogluconate.
作者信息
Thakur C P, Kumar K, Sinha P K, Mishra B N, Pandey A K
机构信息
Patna Medical College and Hospital, India.
出版信息
Br Med J (Clin Res Ed). 1987 Oct 10;295(6603):886-7. doi: 10.1136/bmj.295.6603.886-a.
Abstract
摘要
相似文献
1
Treatment of post-kala-azar dermal leishmaniasis with sodium stibogluconate.
Br Med J (Clin Res Ed). 1987 Oct 10;295(6603):886-7. doi: 10.1136/bmj.295.6603.886-a.
2
Efficacy of prolonged therapy with stibogluconate in post kala-azar dermal leishmaniasis.
Indian J Med Res. 1990 Mar;91:144-8.
3
[Methylglucamine antimoniate and sodium stibogluconate in the treatment of leishmaniasis. Study of 16 cases].
Pathol Biol (Paris). 1985 Jun;33(5 Pt 2):607-10.
4
Prolonged sodium stibogluconate therapy in Indian kala-azar.
J Assoc Physicians India. 1986 Jul;34(7):469-71.
5
Kala-azar: unresponsiveness to prolonged sodium stibogluconate therapy.
J Assoc Physicians India. 1987 Jul;35(7):543.
6
Complications of kala azar and its treatment in Kenya.
East Afr Med J. 1984 Feb;61(2):120-7.
7
Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis).
Trans R Soc Trop Med Hyg. 1984;78(3):391-8. doi: 10.1016/0035-9203(84)90131-7.
8
Post-kala-azar dermal leishmaniasis occurring long after cure of visceral leishmaniasis in Kenya.
East Afr Med J. 1986 May;63(5):365-71.
9
Treatment of cutaneous leishmaniasis with an intralesional antimonial drug (Pentostam).
J Am Acad Dermatol. 1986 Oct;15(4 Pt 1):620-2. doi: 10.1016/s0190-9622(86)70214-4.
10
Combination of sodium stibogluconate and rifampicin in post kala-azar dermal leishmaniasis.
Indian J Dermatol Venereol Leprol. 2007 Jan-Feb;73(1):53-4. doi: 10.4103/0378-6323.30657.
引用本文的文献
1
The story of elimination of visceral leishmaniasis (kala-azar) in India-Challenges towards sustainment.
PLoS Negl Trop Dis. 2025 Aug 19;19(8):e0013321. doi: 10.1371/journal.pntd.0013321. eCollection 2025 Aug.
2
Amphotericin B Deoxycholate Treatment of Post-Kala-Azar Dermal Leishmaniasis in India.
Am J Trop Med Hyg. 2024 Jun 4;111(1):59-63. doi: 10.4269/ajtmh.23-0738. Print 2024 Jul 3.
3
Post-kala-azar dermal leishmaniasis (PKDL) drug efficacy study landscape: A systematic scoping review of clinical trials and observational studies to assess the feasibility of establishing an individual participant-level data (IPD) platform.
PLoS Negl Trop Dis. 2024 Apr 16;18(4):e0011635. doi: 10.1371/journal.pntd.0011635. eCollection 2024 Apr.
4
Para Kala-Azar Dermal Leishmaniasis: A Case Report.
Cureus. 2023 Jan 12;15(1):e33701. doi: 10.7759/cureus.33701. eCollection 2023 Jan.
5
Therapeutic Modalities in Post Kala-azar Dermal Leishmaniasis: A Systematic Review of the Effectiveness and Safety of the Treatment Options.
Indian J Dermatol. 2021 Jan-Feb;66(1):34-43. doi: 10.4103/ijd.IJD_264_20.
6
Efficacy and Safety of Paromomycin in Treatment of Post-Kala-Azar Dermal Leishmaniasis.
ISRN Parasitol. 2014 Mar 6;2014:548010. doi: 10.1155/2014/548010. eCollection 2014.
7
Strategies to overcome antileishmanial drugs unresponsiveness.
J Trop Med. 2014;2014:646932. doi: 10.1155/2014/646932. Epub 2014 Apr 30.
8
Complexities of assessing the disease burden attributable to leishmaniasis.
PLoS Negl Trop Dis. 2008;2(10):e313. doi: 10.1371/journal.pntd.0000313. Epub 2008 Oct 29.
本文引用的文献
1
Renal clearance of pentavalent antimony (sodium stibogluconate).
Lancet. 1980 Aug 2;2(8188):226-9. doi: 10.1016/s0140-6736(80)90120-8.
2
Epidemiological, clinical and therapeutic features of Bihar kala-azar (including post kala-azar dermal leishmaniasis).
Trans R Soc Trop Med Hyg. 1984;78(3):391-8. doi: 10.1016/0035-9203(84)90131-7.
Zotero 插件